Non-Hodgkin's lymphoma (NHL) is a lymphoid neoplasm that is projected to afflict more than 56,800 people in the United States in 1999.62 Although NHL is associated with long-term survival following standard therapy, many patients eventually succumb; 25,700 patients are expected to die of NHL in 1999. High-dose chemotherapy (HDCT) and autologous hematopoietic cell transplantation (AHCT) have been used to treat NHL in various settings with the goal of prolonging disease-free survival (DFS). This article reviews the use of AHCT in treating NHL, including the pertinent clinical data, the source of stem cells, and the preparative regimens with their associated toxicities. The authors hope to convince the reader of the continued need for formal clinical trials to determine the correct and efficient use of AHCT in treating NHL.
No takes yet. Share an insight, caveat, or question.
Johnston et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: